Spyre Therapeutics Inc
For the period ended Dec 31, 2024. Filed Feb 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Feb 27, 2025
SYRE$103.86+7.5%Stored close · as of Nov 6, 2026
Contents
Item 7.
SPYRE THERAPEUTICS, INC.
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Audited Consolidated Financial Statements | |
| Report of Independent Registered Public Accounting Firm (ID 238 PricewaterhouseCoopers LLP) | 94 |
| Consolidated Balance Sheets | 97 |
| Consolidated Statements of Operations | 98 |
| Consolidated Statements of Comprehensive Loss | 99 |
| Consolidated Statements of Changes in Convertible Preferred Stock and Stockholders’ Equity | 100 |
| Consolidated Statements of Cash Flows | 102 |
| Notes to Consolidated Financial Statements | 104 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.